Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

The race to develop a screener.

This is the most current news I can find about CellSearch, the JnJ Veridex device that I think makes onko-sure obsolete:

http://www.xconomy.com/boston/2013/04/16/mgh-veridex-device-enters-challenging-arena-in-tumor-cell-testing/

JnJ has the muscle and the funding to push through a device and get the global medical community to USE it. And we all know that biotech is NOT about saving the world or curing cancer -- it is about making money.

However, this article implies that CellSearch won't get to market for 5-10 years. That probably means 7-15 years.

Is that enough time for someone to try and get the new formulation of DR-70 to market?

I assume you all know that the old formulation of DR-70 contains an ingredient that is no longer available. This was first disclosed in 2008 by Rudd:

http://www.ruddreport.com/Research/amdl/amd_3Q08_11.htm

"Although the Company has obtained approval from the USFDA to market the then current formulation of DR-70® it has been determined that one of the key components of the DR-70® -- the anti-fibrinogen-HRP is limited in supply and additional quantities cannot be purchased. "

For anyone who doesn't know who Rudd is: he was the "analyst" paid by AMDL to "write" about the company. He preceded Garza. Most of the spikes in the historical PPS of this stock between 2004 and 2008 coincided with the release of Rudd's "reports."

If you're interested, here is a piece of analysis I like to share: The previous CEO, Dreher, always found private investors to buy stock in private placements to get funding -- he never took out loans. MacLellan, in contrast, could NOT find private investors, and borrowed money instead. Dreher never had loans to repay, while MacLellan never repaid a loan.

Do you see why I love to follow this company?